 |
196 Products |  |
52 Diseases | | 196 Products |
|
3529 Trials |  |
15381 News |  |
| «12...5152535455565758596061...208209» |
- |||| ribupatide injection (HRS9531 injection) / Kailera Therapeutics
Trial completion date, Trial primary completion date, Monotherapy: A Study of HRS9531 Versus Semaglutide Once Weekly as Add-on Therapy to Metformin Monotherapy or in Combination With SGLT2 Inhibitors in Participants With Type 2 Diabetes (clinicaltrials.gov) - Dec 2, 2024
P3, N=840, Recruiting, Sponsor: Fujian Shengdi Pharmaceutical Co., Ltd.
Trial completion date: Mar 2026 --> Sep 2026 | Trial primary completion date: Mar 2026 --> Sep 2026
- | AiRuiKang (dalpiciclib) / Jiangsu Hengrui Pharma
New trial: Albumin-bound Paclitaxel?Dalpiciclib and AI in ER-Low (1%-10%) HER2-ABC (clinicaltrials.gov) - Dec 1, 2024
P=N/A, N=52, Not yet recruiting, Sponsor: Fujian Medical University
- | zeprumetostat (SHR-2554) / Treeline Biosci, Itari (linperlisib) / Shanghai YingLi Pharma
New P1 trial: Linperlisib Combined With EZH2 Inhibitor in Relapsed/Refractory Peripheral T-cell Lymphoma (PTCL) (clinicaltrials.gov) - Dec 1, 2024
P1, N=33, Not yet recruiting, Sponsor: Institute of Hematology & Blood Diseases Hospital, China
- | AiRuiKa (camrelizumab) / HLB Bio Group
Journal, PD(L)-1 Biomarker, IO biomarker: Chemotherapy combined with immunotherapy in a patient with multiple primary gastric and rectal cancers with good prognosis: A case report. (Pubmed Central) - Nov 29, 2024
According to the results of NGS testing, the multiple primary cancers' patient received personalized treatment and ultimately achieved clinical complete remission. This case highlights the critical role of genetic testing in accurately identifying multiple primary cancer and the value of personalized guidance for patient treatment using NGS in clinical practice.
- || AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
P2 data, Journal, Metastases: Camrelizumab plus apatinib for previously treated advanced adrenocortical carcinoma: a single-arm phase 2 trial. (Pubmed Central) - Nov 29, 2024
P2
The most common grade 3-4 treatment-related adverse events were alanine aminotransferase elevation, aspartate aminotransferase elevation, and lymphopenia. Predefined exploratory analyses indicated that patients with higher peripheral blood CXCR3?+?CD8?+?T cell abundance, lower immunosuppressive CD4?+?T cell abundance, and higher overlap of clonotypes between tumor-infiltrating T cells and circulating T cells, were more likely to respond favorably to the combined therapy.
- ||| AiRuiKa (camrelizumab) / HLB Bio Group
Clinical, P3 data, Journal, Metastases: Camrelizumab plus carboplatin and pemetrexed as first-line therapy for advanced non-squamous non-small-cell lung cancer: 5-year outcomes of the CameL randomized phase 3 study. (Pubmed Central) - Nov 29, 2024
P3
Patients who completed 2 years of camrelizumab had enduring response and impressive OS. Current 5-year updated analysis further supports camrelizumab plus carboplatin and pemetrexed as a standard-of-care for previously untreated advanced non-squamous NSCLC without EGFR/ALK alterations.
- || Review, Journal: Systemic Therapy for Hepatocellular Carcinoma. (Pubmed Central) - Nov 29, 2024
Areas of development include testing immune checkpoint-based regimens in the adjuvant setting after surgery, ablation, or transarterial embolization. Also of interest are studies for patients with Child-Pugh B liver function and adding new checkpoint molecules to the current standard platforms.
- | ribupatide injection (HRS9531 injection) / Kailera Therapeutics
New P1 trial: A Phase 1, single ascending dose study in healthy, overweight and obese participants to investigate safety, tolerability and pharmacokinetics of KAI-9531 subcutaneous injection (EUDRACT) - Nov 29, 2024
P1, N=40, Not yet recruiting, Sponsor: Kailera Therapeutics
- ||| ivarmacitinib (SHR0302) / Jiangsu Hengrui Pharma, Arcutis
P3 data, Journal: Ivarmacitinib, a selective Janus kinase 1 inhibitor, in patients with moderate-to-severe active rheumatoid arthritis and inadequate response to conventional synthetic DMARDs: results from a phase III randomised clinical trial. (Pubmed Central) - Nov 28, 2024
P3
Also of interest are studies for patients with Child-Pugh B liver function and adding new checkpoint molecules to the current standard platforms. Ivarmacitinib may offer a potential therapeutic option for patients with RA who have an inadequate response to csDMARDs, with a safety profile that was generally manageable over 1 year of treatment and similar to other JAK inhibitors.
- || vunakizumab (SHR-1314) / Jiangsu Hengrui Pharma
Review, Journal: Vunakizumab: First Approval. (Pubmed Central) - Nov 28, 2024
In August 2024, vunakizumab was approved in China for the treatment of adult patients with moderate-to-severe plaque psoriasis who are suitable for systemic treatment or phototherapy. This article summarizes the milestones in the development of vunakizumab leading to this first approval for the systemic treatment of moderate-to-severe plaque psoriasis.
- | AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
Enrollment closed: MA-HCC-II-013: Camrelizumab, Apatinib Plus HAIC Versus Camrelizumab and Apatinib for HCC with Portal Vein Invasion: a Randomized Trial (clinicaltrials.gov) - Nov 27, 2024
P3, N=214, Active, not recruiting, Sponsor: Sun Yat-sen University
This article summarizes the milestones in the development of vunakizumab leading to this first approval for the systemic treatment of moderate-to-severe plaque psoriasis. Recruiting --> Active, not recruiting
- | New trial, IO biomarker: Combination of SFRT, PD-L1 Inhibitor, and Anti-VEGF in Advanced Hepatocellular Carcinoma (clinicaltrials.gov) - Nov 27, 2024
P=N/A, N=50, Not yet recruiting, Sponsor: Guiping People's Hospital
- | Irene (pyrotinib) / Jiangsu Hengrui Pharma
Journal: TTK promotes HER2?+?breast cancer cell migration, apoptosis, and resistance to targeted therapy by modulating the Akt/mTOR axis. (Pubmed Central) - Nov 26, 2024
Recruiting --> Active, not recruiting Which implies that TTK is an oncogene in HER2?+?BRCA and is a valuable research target.
- || ruzinurad (SHR 4640) / Jiangsu Hengrui Pharma
PK/PD data, Journal: Effect of Hepatic Impairment on the Pharmacokinetics and Pharmacodynamics of SHR4640, a Selective Human Urate Transporter 1 Inhibitor. (Pubmed Central) - Nov 26, 2024
Mild and moderate hepatic impairment did not have a clinically relevant impact on PK, PD, and safety of SHR4640. SHR4640 can be used in patients with mild to moderate hepatic impairment without the need for dose adjustment.
- ||||| SHR-1826 / Jiangsu Hengrui Pharma
New P1/2 trial: A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With Solid Tumors (clinicaltrials.gov) - Nov 25, 2024
P1/2, N=876, Not yet recruiting, Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd.
- |||| HRS-8080 / Jiangsu Hengrui Pharma, ruzaltatug rezetecan (SHR-A2009) / Jiangsu Hengrui Pharma
Enrollment open: Study of HRS-8080 or SHR-A2009 Combined With Anti-tumor Therapy in Patients With Unresectable or Metastatic Breast Cancer (clinicaltrials.gov) - Nov 25, 2024
P1/2, N=350, Recruiting, Sponsor: Shandong Suncadia Medicine Co., Ltd.
SHR4640 can be used in patients with mild to moderate hepatic impairment without the need for dose adjustment. Not yet recruiting --> Recruiting
- | AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
Journal, HEOR, Cost-effectiveness, Cost effectiveness, Metastases: First-Line Camrelizumab Plus Rivoceranib in Advanced Hepatocellular Carcinoma: A China-Based Cost-Effectiveness Analysis. (Pubmed Central) - Nov 25, 2024
The results of the subgroup analysis demonstrated camrelizumab plus rivoceranib was the most cost-effective in the subgroup with albumin-bilirubin grade 2. At a willingness-to-pay threshold of US$36?780/QALY, camrelizumab plus rivoceranib is likely to be a cost-effective option compared with sorafenib as first-line treatment for advanced hepatocellular carcinoma in China.
- | New trial, Adverse events, IO biomarker: The Effect of Serum Ferritin in irAE (clinicaltrials.gov) - Nov 25, 2024
P=N/A, N=1500, Recruiting, Sponsor: Tianjin Medical University Cancer Institute and Hospital
- || ribupatide injection (HRS9531 injection) / Kailera Therapeutics
Enrollment open: Influence of HRS9531 on Pharmacokinetics of Metformin in Healthy Subjects (clinicaltrials.gov) - Nov 24, 2024
P1, N=20, Recruiting, Sponsor: Fujian Shengdi Pharmaceutical Co., Ltd.
At a willingness-to-pay threshold of US$36?780/QALY, camrelizumab plus rivoceranib is likely to be a cost-effective option compared with sorafenib as first-line treatment for advanced hepatocellular carcinoma in China. Not yet recruiting --> Recruiting
- | AiTan (rivoceranib) / HLB Bio Group, AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma
New P2 trial: Phase II Clinical Study of Adebrelimab Combined with Apatinib in the Treatment of Locally Advanced Non-small Cell Lung Cancer Patients with Radiation Pneumonitis (clinicaltrials.gov) - Nov 22, 2024
P2, N=32, Active, not recruiting, Sponsor: Wei Zhou
- || Review, Journal, Metastases: Clinical benefit of anti-PD-1/PD-L1 plus chemotherapy in first-line treatment for patients over the age of 65 or 75 with metastatic non-small cell lung cancer (NSCLC). (Pubmed Central) - Nov 21, 2024
For patients over the age of 65 with untreated NSCLC, the anti-PD-1/PD-L1 combination with CT, compared with CT alone, is associated with significantly improved OS and PFS. Due to the low number of patients, it is difficult to conclude for those over 75.
- ||| risvutatug rezetecan (GSK5764227) / GSK
New P1 trial: HS-20093-106: ARTEMIS-103: Phase 1b Study of HS-20093 Combinations in Patients with Bone and Soft Tissue Sarcoma. (clinicaltrials.gov) - Nov 21, 2024
P1, N=448, Not yet recruiting, Sponsor: Hansoh BioMedical R&D Company
- |||| HRS-5965 / Jiangsu Hengrui Pharma
Enrollment open: HRS-5965-301: A Study to Evaluate the Efficacy and Safety of Oral HRS-5965 in Adult Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients Who Are Naive to Complement Inhibitor Therapy (clinicaltrials.gov) - Nov 21, 2024
P3, N=70, Recruiting, Sponsor: Chengdu Suncadia Medicine Co., Ltd.
Due to the low number of patients, it is difficult to conclude for those over 75. Not yet recruiting --> Recruiting
- | AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
Trial completion date, Trial primary completion date: Camrelizumab in Combination With Apatinib Mesylate Plus Short-course Chemotherapy for Advanced ESCC (clinicaltrials.gov) - Nov 21, 2024
P2, N=188, Recruiting, Sponsor: The First Affiliated Hospital of Zhengzhou University
Not yet recruiting --> Recruiting Trial completion date: Nov 2026 --> Mar 2027 | Trial primary completion date: Jul 2024 --> Sep 2025
- || Irene (pyrotinib) / Jiangsu Hengrui Pharma
P2 data, Preclinical, Journal: Preclinical study and phase 2 trial of neoadjuvant pyrotinib combined with chemotherapy in luminal/HER2-low breast cancer: PILHLE-001 study. (Pubmed Central) - Nov 20, 2024
P2
In conclusion, neoadjuvant pyrotinib plus chemotherapy has encouraging efficacy and manageable toxicity in women with luminal/HER2-low (IHC 2+/FISH-negative) high-risk EBC. This regimen warrants to be further validated.
- | AnDaJing (vunakizumab) / Jiangsu Hengrui Pharma
New trial: Phase IV Study: Vunakizumab Efficacy and Safety in Moderate-to-severe Plaque Psoriasis (clinicaltrials.gov) - Nov 20, 2024
P=N/A, N=1516, Not yet recruiting, Sponsor: First Hospital of China Medical University
- | AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma, Lenvima (lenvatinib) / Eisai, Merck (MSD)
Trial initiation date: NEO-ERA-01: Neoadjuvant Therapy of HAIC?GEMOX? Combined With Adebrelimab and Lenvatinib for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors (clinicaltrials.gov) - Nov 19, 2024
P2, N=33, Recruiting, Sponsor: The First Affiliated Hospital with Nanjing Medical University
This regimen warrants to be further validated. Initiation date: Mar 2024 --> Dec 2023
- | ByFavo (remimazolam) / PAION, Cosmo Pharma, Mundipharma, Pharmascience, Eagle Pharma, remimazolam tosylate (HR-7056) / Jiangsu Hengrui Pharma
Journal: Effectiveness and safety of remimazolam tosilate versus propofol for sedation in patients undergoing gastrointestinal endoscopy: a randomized controlled trial. (Pubmed Central) - Nov 19, 2024
P=N/A, P4
Initiation date: Mar 2024 --> Dec 2023 Compared to propofol with alfentanil, remimazolam with alfentanil can be used safely and effectively for sedation in patients undergoing gastrointestinal endoscopy, with less impact on the patient's circulatory and respiratory systems and a lower incidence of adverse events.
- | SHR-1806 / Jiangsu Hengrui Pharma
Journal: SHR-1806, a robust OX40 agonist to promote T cell-mediated antitumor immunity. (Pubmed Central) - Nov 19, 2024
Evaluation of SHR-1806 in rhesus monkeys indicates a favorable safety profile and typical pharmacokinetic characteristics. Thus, SHR-1806 emerges as a robust OX40 agonist with promising therapeutic potential.
- || AiRuiKa (camrelizumab) / HLB Bio Group
Clinical, Journal, Real-world evidence, PD(L)-1 Biomarker, IO biomarker, Real-world: Prospective multicenter study of camrelizumab in real-world settings for asian patients with esophageal squamous cell carcinoma. (Pubmed Central) - Nov 19, 2024
P=N/A, P2,
Longer PFS and OS were associated with receiving?>?4 cycles of camrelizumab and having a good LIPI. LIPI can be used as a prognostic biomarker for ESCC patients receiving camrelizumab?+?RT.
- | remimazolam tosylate (HR-7056) / Jiangsu Hengrui Pharma
Journal, Head-to-Head: Efficacy and safety of remimazolam tosylate for patients undergoing off-pump coronary artery bypass grafting: a study protocol for a non-inferiority randomised controlled trial in China. (Pubmed Central) - Nov 19, 2024
P4
The trial results will be submitted to an international peer-reviewed journal. ChiCTR.gov.cn: ChiCTR2400079615.
- | AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
New P2 trial: First-line Treatment of Advanced/unresectable DDLPS (clinicaltrials.gov) - Nov 18, 2024
P2, N=49, Not yet recruiting, Sponsor: Fudan University
- || Endostar (recombinant human endostatin) / Simcere, cisplatin / Generic mfg., AiRuiKa (camrelizumab) / HLB Bio Group
Review, Journal: Highlights of the 2024 ASCO Annual Meeting: radiotherapy of head and neck cancer (Pubmed Central) - Nov 18, 2024
ChiCTR.gov.cn: ChiCTR2400079615. There were two Chinese phase
- || Review, Journal: Special entities of the head and neck region: cancers of the nasopharynx, (para)nasal cavities, salivary glands, and the thyroid gland : Post ASCO 2024 (Pubmed Central) - Nov 18, 2024
P2, P3
There were two Chinese phase In the treatment of locally advanced NPC, a
- | AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
Journal, Metastases: Drug-eluting beads transarterial chemoembolization combined apatinib/camrelizumab for advanced hepatocellular carcinoma with hepatic arterioportal shunts. (Pubmed Central) - Nov 18, 2024
In the treatment of locally advanced NPC, a (1) We investigated a new treatment strategy for patients with advanced HCC and hepatic APS and (2) D-TACE combined with apatinib/camrelizumab demonstrated meaningful efficacy and manageable AEs, making it a promising treatment option.
- | Journal: Comparative efficacy & safety of buparlisib plus fulvestrant, fulvestrant plus dalpiciclib, and ribociclib plus letrozole for postmenopausal, hormone receptor-positive, and HER2-negative breast cancer. (Pubmed Central) - Nov 18, 2024
Dalpiciclib plus fulvestrant is effective and comparatively safe in postmenopausal women with hormone receptor-positive and HER2-negative breast cancers. Dalpiciclib, buparlisib, fulvestrant, and ribociclib cause neutropenia, severe depression, adverse gastroenterological effects, and adverse hepatological effects, respectively.
- | AiTan (rivoceranib) / HLB Bio Group, Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka, AiRuiKa (camrelizumab) / HLB Bio Group
New P2 trial: MA-GC-II-019: Camrelizumab Combined With or Without Apatinib and SOX of Neoadjuvant Treatment for Gastric Cancer (clinicaltrials.gov) - Nov 18, 2024
P2, N=80, Not yet recruiting, Sponsor: Ruijin Hospital
- ||| SHR-A2102 / Jiangsu Hengrui Pharma
Enrollment open: A Trial of SHR-A2102 With Antitumor Therapy in Advanced Urothelial Carcinoma (clinicaltrials.gov) - Nov 18, 2024
P1/2, N=90, Recruiting, Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd.
Dalpiciclib, buparlisib, fulvestrant, and ribociclib cause neutropenia, severe depression, adverse gastroenterological effects, and adverse hepatological effects, respectively. Not yet recruiting --> Recruiting
- | Biomarker, New P2 trial: SPRING: Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGS (clinicaltrials.gov) - Nov 17, 2024
P2, N=200, Not yet recruiting, Sponsor: Peking University Shenzhen Hospital
- | AiRuiKa (camrelizumab) / HLB Bio Group
Journal, PD(L)-1 Biomarker, IO biomarker, Metastases: Clinical effectiveness and safety of Camrelizumab immunotherapy in treating advanced esophageal carcinoma. (Pubmed Central) - Nov 17, 2024
Camrelizumab immunotherapy is highly effective in treating aEC. It can increase the one-year survival rate, and elevate the levels of immunoglobulins and immune molecules while reducing the levels of tumor markers and incidence of side effects.
- | Irene (pyrotinib) / Jiangsu Hengrui Pharma, Herceptin (trastuzumab) / Roche, docetaxel / Generic mfg.
Journal: Pyrotinib and trastuzumab combination treatment synergistically overcomes HER2 dependency in HER2-positive breast cancer: insights from the PHILA trial. (Pubmed Central) - Nov 16, 2024
It can increase the one-year survival rate, and elevate the levels of immunoglobulins and immune molecules while reducing the levels of tumor markers and incidence of side effects. Our findings underscore the robust synergy between pyrotinib and trastuzumab in overcoming HER2 dependency and provide a rationale for pyrotinib, trastuzumab, and docetaxel as one of the optimal choices for patients with untreated HER2-positive metastatic breast cancer, who are dependent on the HER2 signalling cascade.
- | utidelone IV (UTD1) / Beijing Biostar Technologies
Journal: Utidelone combined with anti?angiogenic therapy for the treatment of anthracycline/taxane?treated and endocrine?resistant HR+/HER2? refractory breast cancer with brain metastases: A case report. (Pubmed Central) - Nov 15, 2024
The present case indicates that a combination of utidelone with apatinib/anlotinib exhibited antitumor activity in a patient with HR+/HER2- mBC with BMs. Therefore, this combination offers a promising therapeutic option for the clinical treatment of patients with breast cancer and BMs.
- | Ibrance (palbociclib) / Pfizer, AiRuiKa (camrelizumab) / Elevar Therapeutics
Trial primary completion date: Neoadjuvant Camrelizumab With Palbociclib for Resectable Esophageal Squamous Cell Carcinomas (clinicaltrials.gov) - Nov 15, 2024
P1, N=6, Recruiting, Sponsor: West China Hospital
Therefore, this combination offers a promising therapeutic option for the clinical treatment of patients with breast cancer and BMs. Trial primary completion date: Oct 2024 --> Oct 2025
- | AiRuiKa (camrelizumab) / Elevar Therapeutics
Enrollment open: Pilot Study of Neoadjuvant Chemotherapy Combined With Immunotherapy and Multimodal Thermal Therapy for HER2-negative Breast Cancer (clinicaltrials.gov) - Nov 14, 2024
P=N/A, N=14, Recruiting, Sponsor: Fudan University
Trial primary completion date: Oct 2024 --> Oct 2025 Not yet recruiting --> Recruiting
- ||| ribupatide injection (HRS9531 injection) / Kailera Therapeutics
Trial completion: Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Subcutaneous Injections of HRS9531 in Patients With Type 2 Diabetes Mellitus (clinicaltrials.gov) - Nov 14, 2024
P1, N=64, Completed, Sponsor: Fujian Shengdi Pharmaceutical Co., Ltd.
Not yet recruiting --> Recruiting Recruiting --> Completed
- ||| AiTan (rivoceranib) / HLB Bio Group
Clinical, P3 data, Journal: Comparison of drug-eluting bead transarterial chemoembolization combined with apatinib versus drug-eluting bead transarterial chemoembolization for the treatment of unresectable hepatocellular carcinoma: a randomized, prospective, multicenter phase III trial. (Pubmed Central) - Nov 14, 2024
P4
The commonest apatinib-related TRAEs in the DEB-TACE + apatinib group included hypertension, hand-foot syndrome, fatigue, and diarrhea. In conclusion, DEB-TACE plus apatinib demonstrates superior PFS versus DEB-TACE monotherapy in uHCC cases, maintaining a favorable safety profile with similar occurrences of AEs.
- | Mekinist (trametinib) / Novartis, BeiGene, AiTan (rivoceranib) / HLB Bio Group
Journal: TNFAIP2 promotes HIF1? transcription and breast cancer angiogenesis by activating the Rac1-ERK-AP1 signaling axis. (Pubmed Central) - Nov 14, 2024
The combined application of ERK inhibitors, U0126 or trametinib, with the VEGFR inhibitor Apatinib, additively suppresses angiogenesis and tumor growth of HCC1806 in nude mice. These findings provide new therapeutic strategies for TNBC.
- | Irene (pyrotinib) / Jiangsu Hengrui Pharma, Gilotrif (afatinib) / Boehringer Ingelheim
Journal, Metastases: Pyrotinib as a salvage treatment for patients with HER-2 positive advanced lung adenocarcinoma after the progression of afatinib treatment. (Pubmed Central) - Nov 14, 2024
Progression after prior afatinib treatment does not influence the efficacy of pyrotinib treatment. Pyrotinib may be a salvage option for patients with HER2 mutation who have experienced progression on afatinib.
- | AiTan (rivoceranib) / HLB Bio Group
Journal, Combination therapy: Low-dose apatinib in combination with chemotherapy for hormone receptor-positive, HER2-negative breast cancer with pulmonary lymphangitic carcinomatosis: A case report. (Pubmed Central) - Nov 14, 2024
While further studies are necessary, this therapeutic approach could represent a viable option for managing breast cancer in the context of a visceral crisis. The case also emphasizes the importance of individualized treatment strategies and further research to substantiate these promising findings.
- |||| M9466 / EMD Serono
New P1/2 trial: A Study for the Treatment of Metastatic Prostate Cancer With HRS-1167 Tablets Combined With Abiraterone Acetate Tablets and Prednisone (clinicaltrials.gov) - Nov 14, 2024
P1/2, N=66, Not yet recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.